Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

9431 ARTÍCULOS , VIENDO DEL 6796 AL 6810

Mitochondrial dysfunction and oxidative stress in Parkinson's disease

Subramaniam SR, Chesselet MF.

Prog Neurobiol. 2013 Jul-Aug;106-107:17-32. doi: 10.1016/j.pneurobio.2013.04.004. Epub 2013 Apr 30.

Risk prediction and treatment monitoring are crucial for prevention and management of compulsive dopamine use in Parkinson's disease

van den Heuvel OA.

J Neurol Neurosurg Psychiatry. 2014 Mar;85(3):244. doi: 10.1136/jnnp-2013-305378. Epub 2013 May 14.

Delusional misidentification syndrome and other unusual delusions in advanced Parkinson's disease

Moro A, Munhoz RP, Moscovich M, Arruda WO, Teive HA.

Parkinsonism Relat Disord. 2013 Aug;19(8):751-4. doi: 10.1016/j.parkreldis.2013.04.021. Epub 2013 May 14.

Incidence and pathology of synucleinopathies and tauopathies related to parkinsonism

Savica R, Grossardt BR, Bower JH, Ahlskog JE, Rocca WA.

JAMA Neurol. 2013 Jul;70(7):859-66. doi: 10.1001/jamaneurol.2013.114.

Parkinson disease and exercise

Earhart GM, Falvo MJ.

Compr Physiol. 2013 Apr;3(2):833-48. doi: 10.1002/cphy.c100047.

A survey from 2012 of evidence for the role of neuroinflammation in neurotoxin animal models of Parkinson's disease and potential molecular targets

Ramsey CP, Tansey MG.

Exp Neurol. 2014 Jun;256:126-32. doi: 10.1016/j.expneurol.2013.05.014. Epub 2013 May 28.

Exenatide and the treatment of patients with Parkinson's disease

Aviles-Olmos I, Dickson J, Kefalopoulou Z, Djamshidian A, Ell P, Soderlund T, Whitton P, Wyse R, Isaacs T, Lees A, Limousin P, Foltynie T.

J Clin Invest. 2013 Jun;123(6):2730-6. doi: 10.1172/JCI68295.

Sleep and movement disorders

Giannoccaro MP, Antelmi E, Plazzi G.

Curr Opin Neurol. 2013 Aug;26(4):428-34. doi: 10.1097/WCO.0b013e3283632cef.

The MDS-UPDRS Part II (motor experiences of daily living) resulted useful for assessment of disability in Parkinson's disease

Rodriguez-Blazquez C, Rojo-Abuin JM, Alvarez-Sanchez M, Arakaki T, Bergareche-Yarza A, Chade A, Garretto N, Gershanik O, Kurtis MM, Martinez-Castrillo JC, Mendoza-Rodriguez A, Moore HP, Rodriguez-Violante M, Singer C, Tilley BC, Huang J, Stebbins GT, Goetz CG, Martinez-Martin P.

Parkinsonism Relat Disord. 2013 Oct;19(10):889-93. doi: 10.1016/j.parkreldis.2013.05.017. Epub 2013 Jun 19.

Clinical utility of DaTscan™ (123I-Ioflupane Injection) in the diagnosis of Parkinsonian Syndromes

Roussakis AA, Piccini P, Politis M.

Degener Neurol Neuromuscul Dis. 2013 Jun 27;3:33-39. doi: 10.2147/DNND.S19807. eCollection 2013.

The social impact of Parkinson's disease in Spain: Report by the Spanish Foundation for the Brain

García-Ramos R, López Valdés E, Ballesteros L, Jesús S, Mir P.

Neurologia. 2016 Jul-Aug;31(6):401-13. doi: 10.1016/j.nrl.2013.04.008. Epub 2013 Jun 28.

[Anesthesiological aspects of deep brain stimulation : special features of implementation and dealing with brain pacemaker carriers]

Seemann M, Zech N, Lange M, Hansen J, Hansen E.

Anaesthesist. 2013 Jul;62(7):549-56. doi: 10.1007/s00101-013-2201-y.

Dopamine transporter imaging with [123I]FP-CIT (DaTSCAN) in Parkinson's disease with depressive symptoms: a biological marker for causal relationships?

Grachev ID.

J Neurol Neurosurg Psychiatry. 2014 Feb;85(2):130-1. doi: 10.1136/jnnp-2013-305380. Epub 2013 Jul 6.

[Severe parkinsonism due to metoclopramide: the importance of early recognition]

de Ronde MW, Kingma HJ, Munts AG.

Ned Tijdschr Geneeskd. 2013;157(26):A6037.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias